Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.49 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | BCL2 | P10415 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.40 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6110341 | 1.00 | PPARA (0.49) | PPARAPPARGBCL2MCL1RELA | |
| SCHEMBL3688371 | 0.82 | SRD5A2 (0.51) | PPARABCL2MCL1PPARDKMT2A | |
| SCHEMBL3689063 | 0.82 | MCL1 (0.39) | PPARAPPARGBCL2MCL1PPARD | |
| SCHEMBL3686011 | 0.78 | ITGB3 (0.38) | PPARABCL2MCL1PPARDMAPT | |
| SCHEMBL4477471 | 0.78 | CA12 (0.42) | PPARAPPARGMCL1PPARDMAPT | |
| SCHEMBL3684576 | 0.73 | CA12 (0.40) | MAPTKMT2A | |
| SCHEMBL13509430 | 0.71 | CA12 (0.41) | PPARAPPARGMAPTKMT2ACHRNA7 | |
| SCHEMBL3688215 | 0.70 | CYP4A11 (0.46) | PPARAPPARG | |
| SCHEMBL3683474 | 0.69 | MELK (0.35) | PPARAMAPT | |
| SCHEMBL2156900 | 0.68 | PLA2G2A (0.56) | PPARAPPARGBCL2MCL1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060166983-A1 | Indole derivatives as ppar modulators | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | disclosed |
| EP-1581491-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004092131-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166983-A1 | Indole derivatives as ppar modulators | PPARA, PPARD, PPARG | PPARA 1/4885PPARG 3/4885BCL2 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.